샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784173

세계의 설폰아미드 시장

Sulphonamides
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 291 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

설폰아미드 세계 시장은 2030년까지 1억 6,250만 달러에 달할 전망

2024년에 1억 2,590만 달러로 추정되는 설폰아미드 세계 시장은 2024년부터 2030년까지 CAGR 4.3%로 성장하여 2030년에는 1억 6,250만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석되고 있는 부문 중 하나인 경구제는 CAGR 4.9%를 기록하며 분석 기간 종료시에는 1억 250만 달러에 달할 것으로 예측됩니다. 국소 부문의 성장률은 분석 기간 동안 CAGR 3.6%로 추정됩니다.

미국 시장은 3,430만 달러로 추정, 중국은 CAGR 8.0%로 성장할 것으로 예측

미국의 설폰아미드 시장은 2024년에는 3,430만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3,360만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.7%와 3.4%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.

세계의 설폰아미드 시장 - 주요 동향과 촉진요인 정리

첨단 항생제 시대에도 설폰아미드가 중요한 이유는 무엇일까?

새로운 종류의 항생제가 등장하고 있음에도 불구하고, 설폰아미드는 광범위한 활성, 저렴한 가격, 입증된 임상적 이력 등으로 인해 전 세계 항균제 치료의 기본 요소로 남아있습니다. 가장 초기의 합성 항균제인 설폰아미드는 요로 감염과 호흡기질환에서 안구 감염과 수막염에 이르기까지 세균 감염의 치료에 널리 사용되어 왔습니다. 설폰아미드의 지속적인 의의는 약리학적 다양성과 특히 신약에 대한 접근성이 제한된 지역에서 특정 박테리아 균주에 대한 지속적인 효과에 있습니다. 또한, 설폰아미드는 일반적으로 트리메토프림과 같은 다른 항균제와 병용하여 치료 효과를 높이고 내성균의 발생을 억제하는 데 사용됩니다. 설폰아미드의 사용은 인간의 의약품에 국한되지 않습니다. 설폰아미드는 특히 가축이나 가금류와 같은 수의학 분야에서도 세균 감염을 관리하고 식품 안전에 영향을 미칠 수 있는 질병의 발생을 예방하는 데 중요한 역할을 합니다. 또한, 설폰아미드는 비용 효율적이기 때문에 특히 선진 치료법에 대한 접근성이 제한적인 중저소득 국가에서 공중보건 프로그램에 필수적인 도구가 되고 있습니다. 인간과 동물의 건강에 적용될 수 있기 때문에 안정적인 수요의 기준선이 확보되어 세계 헬스케어 시스템에서 장기적인 유용성이 더욱 강조되고 있습니다.

항균제 내성(AMR)은 설폰아미드 시장에 어떤 영향을 미치고 있는가?

전 세계적으로 항균제 내성(AMR)의 증가는 설폰아미드 시장에 이중으로 영향을 미치고 있습니다. 한편으로는 일반적인 병원균의 내성화로 인해 설폰아미드를 포함한 오래된 항생제에 대한 재평가가 이루어지고 있습니다. 일부 임상 현장, 특히 자원이 부족한 국가에서는 내성균의 증가를 막기 위해 치료제를 순환하거나 병용하는 항균제 스튜어드십 전략의 일환으로 설폰아미드가 치료 프로토콜에 다시 도입되고 있습니다. 한편, AMR에 대한 우려가 높아지면서 인간과 수의학 모두에서 항생제 사용에 대한 규제가 강화되어 설폰아미드의 처방 및 투여 방법에 영향을 미치고 있습니다. 감시 프로그램에서는 항생제 사용 현황을 상세히 추적할 것을 요구하고 있으며, 일부 국가에서는 환경 노출과 교차 내성을 제한하기 위해 농업에서 설폰아미드의 예방적 사용을 제한하거나 단계적으로 폐지하려는 움직임을 보이고 있습니다. 그러나 설폰아미드는 신중하게 사용한다면 항균제의 중요한 도구임에는 변함이 없습니다. 표적 약물 방출, 나노입자 캐리어 등 새로운 제형 및 전달 메커니즘에 대한 연구도 유효성 향상과 내성 위험 감소를 목표로 진행 중입니다. 이러한 진화하는 상황 속에서 시장 환경은 진부화보다는 전 세계 AMR 완화 노력에 따라 관리된 증거 기반 애플리케이션의 필요성에 의해 재구성되고 있습니다.

시장의 안정성에 있어서 동물용 의약품과 농업용의약품은 어떤 역할을 할 수 있을까?

동물용 의약품과 농업용 의약품은 설폰아미드의 세계 수요를 유지하는 데 중요한 역할을 하고 있습니다. 동물용 의약품에서 설폰아미드는 콕시듐증, 살모넬라증, 호흡기질환 등 가축, 가금류, 양식업의 세균성 감염증을 치료하는 데 널리 사용되고 있습니다. 광범위한 스펙트럼 활성을 가지고 있고 상대적으로 저렴하기 때문에 집약적인 축산 시스템, 특히 축산이 급증하는 신흥 시장의 대량 치료 프로토콜에 가장 적합합니다. 또한, 설폰아미드는 종종 약용 사료나 물에 혼합되어 대규모 가축군이나 무리 전체에 효율적으로 투여할 수 있습니다. 이 화합물들은 질병 부담을 줄이고 식용 동물의 생산성을 향상시키기 위한 예방 위생 프로그램에도 채택되어 생산자에게 직접적인 경제적 효과를 가져다주고 있습니다. 그러나 농업에서 설폰아미드의 광범위한 사용은 식품 내 항생제 잔류 및 환경 오염에 대한 우려가 높아지면서 현재 면밀한 조사를 받고 있습니다. 유럽연합(EU), 미국, 중국 등 각 지역의 규제기관은 식품의 안전성을 확보하기 위해 잔류 모니터링 및 최대잔류기준치(MRL) 제도를 도입하고 있습니다. 이러한 규제는 과다 사용을 억제하는 한편, 잔류물질을 포함하지 않는 제제의 기술 혁신과 수의학적 진단 방법을 개선하여 표적 치료를 유도하는 데 도움을 주고 있습니다. 특히 아시아와 아프리카에서 전 세계 단백질 소비가 증가함에 따라 설폰 아미드의 동물용 응용 분야는 계속해서 시장 안정의 중요한 촉진제가 될 것으로 예상됩니다.

오늘날 설폰아미드의 세계 수요와 전략적 관심의 원동력은 무엇인가?

설폰아미드 시장의 성장은 치료 접근성, 산업적 요구, 역학 패턴, 비용 효율성과 관련된 몇 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 개발도상국의 세균성 감염이 지속적으로 높은 부담을 안고 있으며, 설폰아미드는 저렴한 가격으로 널리 이용 가능하기 때문에 1차 또는 2차 선택 약품으로 사용되고 있습니다. 세계보건기구(WHO)와 유니세프(UNICEF)와 같은 조직이 필수 의약품에 대한 공평한 접근을 강조하게 되면서 세계 보건 정책에서 설폰아미드의 역할이 강화되고 있습니다. 또한, 인구 증가와 동물성 단백질에 대한 수요 증가는 특히 빠르게 발전하는 신흥 경제국에서 동물용 항균제의 필요성을 확대하고 있습니다. 설폰아미드는 제조가 비교적 용이하고 유통기한이 길어 제네릭 의약품 제조업체에게 매력적이며, 폭넓은 유통과 경쟁력 있는 가격 설정이 보장됩니다. 연구 측면에서는 구약의 재사용이 다시 주목받고 있으며, 특히 무시당하는 열대성 질병과 내성 병원체 문제에서 설폰아미드가 다시 주목받고 있습니다. 또한, 설폰아미드의 병용요법, 외용제, 소아용 제제와의 통합으로 그 임상적 활용도가 확대되고 있습니다. 인간과 동물의 건강, 규제 변화, 새로운 치료 전략 등 이러한 역학은 설폰아미드를 항균제 시장의 지속적인 구성요소로 자리 매김하면서 세계 수요를 유지하고 있습니다.

부문

투여 경로(경구제, 국소제, 기타), 용도(피부 감염증, 위장관감염증, 요로감염, 호흡기관감염증, 기타)

조사 대상 기업 사례

  • AA Pharma Inc.
  • Abbott Laboratories
  • Akorn Operating Company LLC
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Clinivex
  • Creative Biolabs Laboratories
  • Dishman Carbogen Amcis Ltd
  • Dr. Reddy's Laboratories
  • Elam Pharma
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Lexine Technochem Pvt. Ltd
  • LGC Standards
  • Manus Aktteva Biopharma LLP
  • Monarch Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stratechem(I) Pvt. Ltd
  • Sun Pharmaceutical Industries Ltd
  • TCI America
  • Teva Pharmaceutical Industries Ltd
  • Valeo Pharma Inc.
  • Viatris Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Sulphonamides Market to Reach US$162.5 Million by 2030

The global market for Sulphonamides estimated at US$125.9 Million in the year 2024, is expected to reach US$162.5 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$102.5 Million by the end of the analysis period. Growth in the Topical segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.3 Million While China is Forecast to Grow at 8.0% CAGR

The Sulphonamides market in the U.S. is estimated at US$34.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$33.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Sulphonamides Market - Key Trends & Drivers Summarized

Why Are Sulphonamides Still Relevant in the Era of Advanced Antibiotics?

Despite the emergence of newer classes of antibiotics, sulphonamides remain a foundational element in global antimicrobial therapy, particularly due to their broad-spectrum activity, affordability, and proven clinical history. As some of the earliest synthetic antimicrobials, sulphonamides have been widely used to treat bacterial infections ranging from urinary tract infections and respiratory illnesses to eye infections and meningitis. Their continued relevance stems from both their pharmacological versatility and enduring efficacy against certain strains of bacteria, especially in regions with limited access to newer drugs. Moreover, sulphonamides are commonly used in fixed-dose combinations with other antimicrobials like trimethoprim to enhance therapeutic outcomes and reduce resistance development. Their use is not limited to human medicine-sulphonamides are also critical in veterinary applications, particularly in livestock and poultry, where they help manage bacterial infections and prevent disease outbreaks that could impact food safety. In addition, the cost-effectiveness of sulphonamides makes them an indispensable tool in public health programs, especially in low- and middle-income countries where access to more advanced therapies may be constrained. Their dual application across human and animal health ensures a stable baseline of demand, further underscoring their long-standing utility in global healthcare systems.

How Is Antimicrobial Resistance (AMR) Influencing the Sulphonamides Market?

The global rise in antimicrobial resistance (AMR) is having a dual impact on the sulphonamides market. On one hand, increasing resistance among common pathogens has prompted a re-evaluation of older antibiotics, including sulphonamides, which may still retain effectiveness against specific bacterial strains. In some clinical settings, particularly in resource-limited countries, sulphonamides are being reintroduced into treatment protocols as part of antimicrobial stewardship strategies that rotate or combine therapies to prevent resistance build-up. On the other hand, growing concerns over AMR have led to more stringent regulatory controls on the use of antibiotics in both human and veterinary medicine, influencing how sulphonamides are prescribed and administered. Surveillance programs now require detailed tracking of antibiotic usage, and some countries are moving to restrict or phase out prophylactic use of sulphonamides in agriculture to limit environmental exposure and cross-resistance. However, when used judiciously, sulphonamides remain an important tool in the antimicrobial arsenal. Research into novel formulations and delivery mechanisms-such as targeted drug release and nanoparticle carriers-is also underway to improve efficacy and reduce resistance risks. In this evolving landscape, the market for sulphonamides is being reshaped not by obsolescence, but by the need for controlled, evidence-based applications that align with global AMR mitigation efforts.

What Role Do Veterinary and Agricultural Applications Play in Market Stability?

Veterinary and agricultural uses play a significant role in maintaining the global demand for sulphonamides. In animal health, sulphonamides are widely used to treat bacterial infections in livestock, poultry, and aquaculture, including conditions like coccidiosis, salmonellosis, and respiratory diseases. Their broad-spectrum activity and relatively low cost make them ideal for mass treatment protocols in intensive farming systems, especially in emerging markets where livestock production is increasing rapidly. Moreover, sulphonamides are often included in medicated feed or water, allowing for efficient delivery across large herds or flocks. These compounds are also employed in preventive health programs to reduce disease burden and improve productivity in food animals, which has a direct economic impact for producers. However, the extensive use of sulphonamides in agriculture is now being scrutinized under growing concerns about antibiotic residues in food products and environmental contamination. Regulatory agencies across regions-including the European Union, the United States, and China-have introduced residue monitoring and maximum residue limit (MRL) frameworks to ensure food safety. While such regulations may restrain overuse, they are also prompting innovation in residue-free formulations and improved veterinary diagnostics to guide targeted treatment. As global protein consumption rises, particularly in Asia and Africa, the veterinary application of sulphonamides is expected to remain a key driver of market stability.

What’s Driving Global Demand and Strategic Interest in Sulphonamides Today?

The growth in the sulphonamides market is driven by several factors related to therapeutic access, industrial need, epidemiological patterns, and cost-efficiency. One of the key drivers is the continued high burden of bacterial infections in developing regions, where sulphonamides serve as first-line or second-line therapy due to their affordability and widespread availability. The growing emphasis on equitable access to essential medicines by organizations such as the WHO and UNICEF reinforces the role of sulphonamides in global health policies. Additionally, population growth and the increasing demand for animal protein are expanding the need for veterinary antimicrobials, particularly in fast-developing agricultural economies. The relative ease of manufacturing and long shelf life of sulphonamides make them attractive to generic pharmaceutical producers, ensuring broad distribution and competitive pricing. On the research front, renewed interest in repurposing older drugs has brought sulphonamides back into focus, especially in the context of neglected tropical diseases and resistant pathogens. Furthermore, the integration of sulphonamides into combination therapies, topical treatments, and pediatric formulations is expanding their clinical versatility. Collectively, these dynamics-spanning human and animal health, regulatory shifts, and emerging therapeutic strategies-are sustaining global demand and positioning sulphonamides as an enduring component of the antimicrobial market.

SCOPE OF STUDY:

The report analyzes the Sulphonamides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Topical, Others); Application (Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AA Pharma Inc.
  • Abbott Laboratories
  • Akorn Operating Company LLC
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Clinivex
  • Creative Biolabs Laboratories
  • Dishman Carbogen Amcis Ltd
  • Dr. Reddy's Laboratories
  • Elam Pharma
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Lexine Technochem Pvt. Ltd
  • LGC Standards
  • Manus Aktteva Biopharma LLP
  • Monarch Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stratechem (I) Pvt. Ltd
  • Sun Pharmaceutical Industries Ltd
  • TCI America
  • Teva Pharmaceutical Industries Ltd
  • Valeo Pharma Inc.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sulphonamides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Prevalence of Infectious Diseases in Developing Regions Propels Demand for Cost-Effective Antimicrobials
    • Combination Therapies and Fixed-Dose Formulations Strengthen the Business Case for Sulphonamide Use
    • Veterinary Applications in Livestock and Poultry Expand the Addressable Market in Animal Health
    • Re-Evaluation of Older Drugs Amid Antimicrobial Resistance Drives Renewed Use in Clinical Practice
    • Access to Essential Medicines Frameworks Sustain Sulphonamide Use in Public Health Programs
    • Long Shelf Life and Ease of Production Generate Competitive Advantage for Generic Manufacturers
    • Use in Preventive Animal Health Programs Drives Market Adoption in Intensive Farming Operations
    • Growing Application in Combination Antimalarial and Antibacterial Therapies Expands Formulation Potential
    • Surveillance of Antimicrobial Resistance Creates Demand for Controlled, Targeted Usage Protocols
    • Rising Research in Neglected Tropical Diseases Positions Sulphonamides for New Therapeutic Roles
    • Expanding Veterinary Infrastructure and Pet Ownership Trends Drive Growth in Companion Animal Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sulphonamides Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sulphonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Skin Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastro Intestinal Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastro Intestinal Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gastro Intestinal Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Respiratory Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Sulphonamides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Sulphonamides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Sulphonamides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Sulphonamides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제